Can ketamine clinics use Google Ads?

Sometimes, with limits. Google restricts prescription drug terms in ads, landing pages, and keywords, and US telemedicine providers need LegitScript accreditation plus Google certification. Ads that use ketamine in the text, keywords, or landing page fall under that restriction, so expect disapprovals without the right certification. Build organic search and your Google Business Profile first, then add paid search.

Can we advertise ketamine therapy on Facebook and Instagram?

Meta requires LegitScript certification for ads that promote prescription drugs and shows those ads only to people 18 and older in certified countries. We do not recommend swapping in vague terms to get past review. It can get your ad account disabled, and it hides from patients what you actually offer.

Should we market Spravato separately from IV ketamine?

Yes. Spravato is an FDA-approved esketamine nasal spray for adults with treatment-resistant depression, usually defined as an inadequate response to at least two oral antidepressants. It is given in a REMS-certified setting with at least two hours of monitoring, and many insurers cover it with prior authorization. IV ketamine is off-label and mostly self-pay. A JAMA Network Open review of clinic ads found infusion prices from $360 to $2,500, and an initial series is usually six infusions. Patients compare the two, so each needs its own page.

What keywords should ketamine clinics target?

Target three groups. Problem searches, such as "nothing works for my depression" and "treatment-resistant depression options." Treatment searches, such as "Spravato near me" and "IV ketamine clinic" with your city. Decision searches, such as "ketamine vs Spravato," "ketamine side effects," and "is ketamine covered by insurance." The problem and decision searches are where educational content builds trust before a consultation.

Can we say ketamine works for PTSD, anxiety, or chronic pain?

You can describe the research accurately, but the evidence is thinner than for depression. Studies of ketamine for PTSD and anxiety are smaller and their results are mixed, and chronic pain results vary by condition. Cite specific studies, say research is ongoing, and do not imply the same level of support that exists for treatment-resistant depression.

How large is the treatment-resistant depression population?

A 2021 study in The Journal of Clinical Psychiatry estimated that 8.9 million US adults had medication-treated major depressive disorder, and about 2.8 million of them (30.9%) had treatment-resistant depression. It is a modeled estimate from insurance claims, so use it as context, not as a forecast of demand in your area.

What should our website say about safety and side effects?

List common side effects such as dissociation, nausea, sedation, and a temporary rise in blood pressure, and say who should not receive treatment. Explain your screening, your monitoring period, and who supervises each session. Clear risk information builds trust with referring clinicians, and it helps prospective patients self-screen before they call.

How do we build physician referral relationships?

Start with what referring clinicians need: eligibility and exclusion criteria, how you monitor blood pressure and dissociation, and how you report back. With patient consent, send a short summary after each referred patient finishes their initial series. Ask every new patient how they found you so you know which relationships produce referrals.

Do new state laws affect our marketing?

They can. Georgia's HB 717 requires a state license for ketamine clinics starting July 1, 2027, and limits who can own a new clinic and who can administer treatment. Texas has proposed standards for IV ketamine clinics. If your website names staff roles, ownership, or supervision levels, review that copy against your state's current rules.

What about at-home or telehealth ketamine?

The FDA warned in October 2023 that at-home use of compounded ketamine carries extra risk because no clinician monitors the patient. DEA telemedicine flexibilities allow controlled substance prescribing without an in-person visit through December 31, 2026, and the permanent rules are not final. If you offer at-home treatment, your marketing has to explain screening, supervision, and those limits plainly.

Marketing for Ketamine Clinics

Grow Your Ketamine Clinic Without Claims You Cannot Defend

Ketamine clinics market two different things: off-label ketamine, which is FDA approved only as an anesthetic, and Spravato, which has its own label and REMS rules. Google and Meta restrict prescription drug ads, and state medical boards are writing new rules for these clinics. We help ketamine and Spravato clinics build search visibility and referral channels with copy that holds up to that scrutiny.

Discuss Your Marketing Strategy

The Challenge

Obstacles limiting your practice's growth

Understanding the friction points that prevent your practice from reaching its full potential.

Ad Platforms Treat Ketamine as a Restricted Drug

Google restricts prescription drug terms in ads, landing pages, and keywords. Meta requires LegitScript certification before most prescription drug ads can run. On Instagram, a search for ketamine returns a warning that the term may be associated with the sale of drugs.

Common Clinic Claims Draw Regulatory Attention

The FDA stated in October 2023 that ketamine is not approved for any psychiatric disorder. A KFF Health News review still found clinic ads promising rapid relief and downplaying risk, and some Google ads called ketamine nonaddictive. Copy like that invites FTC and medical board attention and costs you credibility with referring psychiatrists.

Patients Search for the Problem, Not the Treatment

Many people who might qualify for ketamine or Spravato have never considered either. After two or three medications fail, they search phrases like "nothing works for my depression." A site built only around "ketamine clinic near me" misses that earlier, larger group.

Introduction Letters Rarely Become Referrals

Psychiatrists and primary care physicians want to know your screening criteria, how you monitor patients, and what you send back after treatment. A one-time announcement letter answers none of that. Referral relationships build over months of consistent clinical communication.

State Rules Are Still Changing

Georgia's HB 717, signed in May 2026, requires ketamine clinics to hold a state license starting July 1, 2027. The Texas Medical Board has been drafting and revising standards for IV ketamine clinics throughout 2026. Website copy about ownership, staffing, and supervision has to keep pace.

Our Approach

The Solution

We build ketamine clinic marketing on channels that do not depend on ad approval: organic search, Google Business Profile, email, and physician referrals. Every claim on your site traces back to the FDA label, the published research, or your own clinical protocol.

SEO for condition-first searches like treatment-resistant depression, alongside Spravato and IV ketamine terms.

Separate pages for IV ketamine and Spravato, because cost, insurance, eligibility, and FDA status differ.

Treatment pages that list side effects, contraindications, and screening criteria next to benefits.

Clinician bios and medical review dates that show who supervises care.

Referral materials for psychiatrists and PCPs covering intake criteria, monitoring, and follow-up reporting.

Google Business Profile setup with accurate categories, services, and hours.

De-identified, aggregate outcome reporting, such as average PHQ-9 change, in place of testimonials that imply typical results.

The Landscape

The Rules That Shape Ketamine Clinic Marketing

Ketamine marketing answers to FDA labeling, FTC advertising law, state medical boards, and platform policy at the same time. Your copy has to satisfy all four.

FDA Status, Stated Precisely

Spravato is FDA approved for treatment-resistant depression in adults, including as a standalone treatment since January 2025, and is given only in REMS-certified settings. Generic ketamine is approved as an anesthetic, and the FDA's 2023 warning notes it is not approved for any psychiatric disorder. Your copy never calls IV or oral ketamine FDA approved for depression.

Evidence Behind Every Claim

The FTC expects competent and reliable scientific evidence for health claims. We leave out words like cure, immediate, and guaranteed, and we pair benefits with risks such as dissociation, a temporary rise in blood pressure, and misuse potential.

Visible Medical Oversight

A 2026 study of 233 New York-area clinics advertising off-label ketamine found that only 51.5% listed a medical doctor on their team. Name your medical director, monitoring protocol, and emergency plan so patients and referrers can see who is responsible for care.

Channels That Do Not Need Ad Approval

Organic search, your Google Business Profile, email, and referral networks carry most of the growth. Paid ads become an option after you meet Google's healthcare policy and Meta's LegitScript requirement.

FAQ

Frequently Asked Questions

Can't find the answer you're looking for?
Reach out to our support team.

Get Started

Build Visibility for Your Ketamine Practice

Reach patients researching treatment-resistant depression with marketing that shows your medical oversight and stays within platform and board rules.

Discuss Your Marketing Strategy Schedule a Call

No Long-Term Contracts

Work with us on your terms. Cancel anytime if we're not delivering results.